FST and Duchenne muscular dystrophy: Several strategies based on the myostatin-follistatin pathway are currently in clinical trials for muscle pathologies such as Duchenne muscular dystrophy (DMD), Becker muscular dystrophy and inclusion body myositis but have yet to be initiated for SMA.